MiNK Therapeutics, announced that it has begun dosing patients with solid tumor cancers with AgenT-797 alone and in combination with approved anti-PD-1 checkpoint inhibitors in a Phase 1 open-label clinical trial. In the ongoing clinical trials, it has been demonstrated that AgenT-797 can be administered tolerably in up to 1 billion cells per dose without lymphodepletion, with no evidence of cytokine release syndrome or neurotoxicity. Pre-clinical data has demonstrated the persistence, trafficking, and anti-cancer activity of AgenT-797, in both solid and liquid cancers.

This phase 1, open-label study is evaluating the safety, tolerability, and preliminary clinical activity of AgenT-797, an unmodified, allogeneic iNKT cell therapy, alone and in combination with approved immune checkpoint inhibitors in patients with relapsed/refractory solid tumors (NCT05108623).